ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone734-335-0468
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10,000.00
Profitability
Miscellaneous
Employees11
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable
ENDRA Life Sciences (NASDAQ:NDRA) Frequently Asked Questions
What is ENDRA Life Sciences' stock symbol?
ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA."
How were ENDRA Life Sciences' earnings last quarter?
ENDRA Life Sciences Inc (NASDAQ:NDRA) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.03. View ENDRA Life Sciences' Earnings History.
When is ENDRA Life Sciences' next earnings date?
What price target have analysts set for NDRA?
3 brokerages have issued 12-month price objectives for ENDRA Life Sciences' shares. Their predictions range from $6.00 to $6.00. On average, they anticipate ENDRA Life Sciences' stock price to reach $6.00 in the next year. This suggests a possible upside of 395.9% from the stock's current price. View Analyst Price Targets for ENDRA Life Sciences.
What is the consensus analysts' recommendation for ENDRA Life Sciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ENDRA Life Sciences.
Has ENDRA Life Sciences been receiving favorable news coverage?
News articles about NDRA stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ENDRA Life Sciences earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for ENDRA Life Sciences.
Are investors shorting ENDRA Life Sciences?
ENDRA Life Sciences saw a drop in short interest in September. As of September 30th, there was short interest totalling 770,400 shares, a drop of 7.7% from the August 30th total of 834,500 shares. Based on an average trading volume of 77,400 shares, the short-interest ratio is currently 10.0 days. Approximately 10.9% of the company's stock are short sold. View ENDRA Life Sciences' Current Options Chain.
Who are some of ENDRA Life Sciences' key competitors?
Some companies that are related to ENDRA Life Sciences include IRIDEX (IRIX), Fc Global Realty (FCRE), Precision Optics (PEYE), Digirad (DRAD), Viveve Medical (VIVE), Non-Invasive Monitoring Systems (NIMU), CHF Solutions (CHFS), Nexeon Medsystems (NXNN), Vaso (VASO), Reshape Lifesciences (RSLS), Escalon Medical (ESMC), Trimedyne (TMED), Guided Therapeutics (GTHP), Echo Therapeutics (ECTE) and Magna-Lab (MAGAA).
What other stocks do shareholders of ENDRA Life Sciences own?
Who are ENDRA Life Sciences' key executives?
ENDRA Life Sciences' management team includes the folowing people:
- Mr. Francois Michelon, Chairman & CEO (Age 53)
- Mr. David R. Wells, CFO & Sec. (Age 57)
- Mr. Michael Thornton, Chief Technology Officer (Age 51)
- Dr. Jonathan Behr Ph.D., Co-Founder
- Mr. Steve Freeman, HR Leader
When did ENDRA Life Sciences IPO?
(NDRA) raised $10 million in an IPO on Friday, February 3rd 2017. The company issued 2,000,000 shares at $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO.
How do I buy shares of ENDRA Life Sciences?
Shares of NDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ENDRA Life Sciences' stock price today?
One share of NDRA stock can currently be purchased for approximately $1.21.
How big of a company is ENDRA Life Sciences?
ENDRA Life Sciences has a market capitalization of $8.02 million and generates $10,000.00 in revenue each year. The company earns $-9,800,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. ENDRA Life Sciences employs 11 workers across the globe.View Additional Information About ENDRA Life Sciences.
What is ENDRA Life Sciences' official website?
How can I contact ENDRA Life Sciences?
ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The company can be reached via phone at 734-335-0468 or via email at [email protected]
MarketBeat Community Rating for ENDRA Life Sciences (NASDAQ NDRA)
MarketBeat's community ratings are surveys of what our community members think about ENDRA Life Sciences and other stocks. Vote "Outperform" if you believe NDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NDRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
